Ligands and receptors in human cytomegalovirus entry: current therapies and new directions

Drug Discov Today. 2023 Nov 20:103833. doi: 10.1016/j.drudis.2023.103833. Online ahead of print.ABSTRACTThe demand for human cytomegalovirus (HCMV) vaccines was first raised by a committee convened during the 1990s. A comprehensive investigation into the mechanism of viral infection supports the prioritization of developing drugs or vaccines that specifically target receptors and ligands involved in the infection process. As primary targets for neutralizing antibodies to combat HCMV, viral ligands (trimer, pentamer, and glycoprotein B) have crucial roles and exhibit substantial antiviral potential, which could be exploited for breakthroughs in antiviral research.PMID:37992888 | DOI:10.1016/j.drudis.2023.103833

Source: Drug Discovery Today - November 22, 2023 Category: Drugs & Pharmacology Authors: Min Zhang Xiaochen Wang Jianshe Li Fujun Peng Zhijun Liu Zhe-Sheng Chen Source Type: research